Is There a Role for "Watch and Wait" in Patients With Mantle Cell Lymphoma?

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 189-193

  Martin, Peter ^a   Leonard, John ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; KI 67 ANTIGEN;

ARTICLE; CANCER RESEARCH; CELL PROLIFERATION; CLINICAL OBSERVATION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MEDICAL DECISION MAKING; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL; SURVIVAL TIME; TREATMENT INDICATION;

HUMANS; LYMPHOMA, MANTLE-CELL; OBSERVATION; PROGNOSIS;

EID: 79960487923     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.010     Document Type: Article

References (38)

1. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
2. Martin P., Chadburn A., Christos P., et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008, 19:1327-1330.
3. Romaguera J.E., Fayad L.E., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
4. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
5. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
6. Hermine O., Hoster E., Walewski J., et al. Alternating Courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 2010, 116:110.
7. Richard P., Vassallo J., Valmary S., Missoury R., Delsol G., Brousset P. "In situ-like" mantle cell lymphoma: a report of two cases. J Clin Pathol 2006, 59:995-996.
8. Aqel N., Barker F., Patel K., Naresh K. In-situ mantle cell lymphoma-a report of two cases. Histopathology 2008, 52:256-260.
9. Racke F., Simpson S., Christian B., Blum K.A., Hasserjian R., Zhao W. Evidence of long latency periods prior to development of mantle cell lymphoma. ASH Annual Meeting Abstracts 2010, 116:323.
10. Bassarova A., Tierens A., Lauritzsen G., Fosså A., Delabie J. Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?. Virchows Arch 2008, 453:407-411.
11. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
12. Rawstron A.C., Bennett F.L., O'Connor S.J.M., et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008, 35:9575-9583.
13. Martin P., Chadburn A., Christos P., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
14. Eve H.E., Furtado M.V., Hamon M.D., Rule S.A.J. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009, 27:e189-e190.
15. Fernàndez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
16. Nodit L., Bahler D., Jacobs S., Locker J., Swerdlow S. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003, 34:1030-1034.
17. Thieblemont C., Houlgatte R., Felman P., et al. Indolent mantle cell lymphoma (MCL): a retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profiling analysis. ASH Annual Meeting Abstracts 2008, 112:1780.
18. Evens A.M., Kelemen K., Aranha O., et al. Survival of CD23-positive (CD23+) mantle cell lymphoma (MCL) compared to classic CD23-negative (CD23-) MCL: biologic correlates and clinical outcomes in a 10-year analysis. ASCO Meeting Abstracts 2007, 25(18 suppl):8039.
19. Gao J., Peterson L., Nelson B., Goolsby C., Chen Y.-H. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009, 132:699-706.
20. Fu K., Weisenburger D.D., Greiner T.C., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
21. Quintanilla-Martinez L., Slotta-Huspenina J., Koch I., et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 2009, 94:1595-1598.
22. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
23. Hoster E., Hasford J., Hermine O., et al. Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in an independent prospective patient cohort. ASH Annual Meeting Abstracts 2009, 114:138.
24. Ruan J., Martin P., Furman R.R., et al. CHOP-R + bortezomib as initial therapy for mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts 2009, 114:2682.
25. Smith S.D., Hsi E.D., Bolwell B.J., Maggiotto A., Effinger M., Sweetenham J.W. Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): a valuable tool for risk stratification in mantle cell lymphoma. ASH Annual Meeting Abstracts 2009, 114:2703.
26. Geisler C.H., Kolstad A., Laurell A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010, 115:1530-1533.
27. Determann O., Hoster E., Ott G., et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385-2387.
28. Klapper W., Hoster E., Determann O., et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009, 2:103-111.
29. Schaffel R., Hedvat C.V., Teruya-Feldstein J., et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010, 21:133-139.
30. Leonard J.P., LaCasce A., Smith M.R., et al. Cdk4/6 Inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. ASH Annual Meeting Abstracts 2008, 112:264.
31. Thorsélius M., Walsh S., Eriksson I., et al. Somatic hypermutation and VH gene usage in mantle cell lymphoma. Eur J Haematol 2002, 68:217-224.
32. Lai R., Lefresne S.V., Franko B., et al. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol 2006, 19:1498-1505.
33. Schraders M., Oeschger S., Kluin P.M., et al. Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Mod Pathol 2009, 22:416-425.
34. Kienle D., Krober A., Katzenberger T., et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
35. Walsh S.H., Thorselius M., Johnson A., et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003, 101:4047-4054.
36. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
37. Roschewski M., Weniger M., Kurdziel K., et al. FDG-PET as a marker of tumor proliferation compared to gene-expression proliferation scores, MIB1%, and LDH in untreated mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts 2010, 116:3093.
38. Yap J., Rastarhuyeva I., Yu J., et al. Comparison of FDG- and FLT-PET/CT in a multi-center phase Ib trial of a novel anti-proliferative cyclin dependent kinase (cdk) inhibitor in treatment of recurrent mantle cell lymphoma. J Nucl Med Meeting Abstracts 2008, 49:147P-c.